Literature DB >> 1063590

Adenosine deaminase activity in peripheral blood cells of patients with haematological malignancies.

J Meier, M S Coleman, J J Hutton.   

Abstract

Adenosine deaminase (EC 3.5.4.4, ADA) has been assayed in lymphocytes, granulocytes and erythrocytes from 45 patients with haematological malignancies. Activities were uniformly low in lymphocytes from patients with chronic lymphocytic leukaemia. Variable, but abnormal activities were frequently found in multiple myeloma, untreated lymphoma and leukaemic reticuloendotheliosis. High values were observed in lymphocytes from patients with lymphoma during intensive combination chemotherapy. ADA levels in lymphocytes were not correlated with levels in granulocytes or erythrocytes. ADA was elevated in blasts of patients with acute lymphocytic and myelogenous leukaemias but the ranges of activities per cell were so similar that ADA assay is unlikely to be of major help in distinguishing the two diseases.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1063590      PMCID: PMC2024973          DOI: 10.1038/bjc.1976.45

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  11 in total

1.  Terminal deoxynucleotidyl transferase and adenosine deaminase in human lymphoblastoid cell lines.

Authors:  M S Coleman; J J Hutton
Journal:  Exp Cell Res       Date:  1975-09       Impact factor: 3.905

2.  The B-lymphocyte nature of the hairy cell of leukaemic reticuloendotheliosis.

Authors:  D Catovsky; J E Pettit; J Galetto; A Okos; D A Galton
Journal:  Br J Haematol       Date:  1974-01       Impact factor: 6.998

3.  Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity.

Authors:  E R Giblett; J E Anderson; F Cohen; B Pollara; H J Meuwissen
Journal:  Lancet       Date:  1972-11-18       Impact factor: 79.321

4.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

5.  Identification of the enzymatic pathways of nucleotide metabolism in human lymphocytes and leukemia cells.

Authors:  E M Scholar; P Calabresi
Journal:  Cancer Res       Date:  1973-01       Impact factor: 12.701

6.  Partial purification and properties of the common inherited forms of adenosine deaminase from human erythrocytes.

Authors:  W R Osborne; N Spencer
Journal:  Biochem J       Date:  1973-05       Impact factor: 3.857

7.  Multiple forms of human adenosine deaminase. I. Purification and characterization of two molecular species.

Authors:  H Akedo; H Nishihara; K Shinkai; K Komatsu; S Ishikawa
Journal:  Biochim Biophys Acta       Date:  1972-07-13

8.  Effect of neuraminidase and papain treatment on lectin-induced agglutination of Novikoff tumor cells and assay of lectin receptor activity of the glycopeptides released from the cell surface by papain.

Authors:  G Neri; M C Giuliano; S Capetillo; E B Gilliam; D C Hixson; E F Walborg
Journal:  Cancer Res       Date:  1976-01       Impact factor: 12.701

9.  Severe combined immunodeficiency and adenosine deaminase deficiency.

Authors:  R Parkman; E W Gelfand; F S Rosen; A Sanderson; R Hirschhorn
Journal:  N Engl J Med       Date:  1975-04-03       Impact factor: 91.245

10.  Adenosine deaminase activity in leukaemia.

Authors:  J F Smyth; K R Harrap
Journal:  Br J Cancer       Date:  1975-05       Impact factor: 7.640

View more
  13 in total

1.  PORPHOBILINOGEN DEAMINASE AND ADENOSINE DEAMINASE ACTIVITY AS A POSSIBLE DIAGNOSTIC AID IN LYMPHATIC LEUKEMIAS.

Authors:  Alka N Sontakke; Y V Sharma
Journal:  Med J Armed Forces India       Date:  2017-06-26

2.  Correlation of adenosine deaminase activity with cell surface markers in acute lymphoblastic leukemia.

Authors:  J F Smyth; D G Poplack; B J Holiman; B G Leventhal; G Yarbro
Journal:  J Clin Invest       Date:  1978-09       Impact factor: 14.808

Review 3.  Biochemical enzyme analysis in acute leukaemia.

Authors:  H G Drexler; G Gaedicke; J Minowada
Journal:  J Clin Pathol       Date:  1985-02       Impact factor: 3.411

4.  Enzymes of the purine interconversion system in chronic lymphatic leukemia: decreased purine nucleoside phosphorylase and adenosine deaminase activity.

Authors:  H Ludwig; R Kuzmits; H Pietschmann; M M Müller
Journal:  Blut       Date:  1979-11

5.  Alteration of adenosine deaminase levels in peripheral blood lymphocytes of patients with gastric cancer.

Authors:  O Kojima; T Majima; Y Uehara; T Yamane; Y Fujita; T Takahashi; S Majima
Journal:  Jpn J Surg       Date:  1985-03

6.  Myelomatous pleural effusion as an initial sign of multiple myeloma-a case report and review of literature.

Authors:  Li-Li Zhang; Yuan-Yuan Li; Cheng-Ping Hu; Hua-Ping Yang
Journal:  J Thorac Dis       Date:  2014-07       Impact factor: 2.895

7.  Adenosine deaminase, 5'-nucleotidase, xanthine oxidase, superoxide dismutase, and catalase activities in gastric juices from patients with gastric cancer, ulcer, and atrophic gastritis.

Authors:  I Durak; N Ormeci; O Akyol; O Canbolat; M Kavutçu; M Bülbül
Journal:  Dig Dis Sci       Date:  1994-04       Impact factor: 3.199

Review 8.  Enzyme and membrane markers in leukaemia: recent developments.

Authors:  A V Hoffbrand; G Janossy
Journal:  J Clin Pathol       Date:  1981-03       Impact factor: 3.411

9.  Glucocorticoid receptor concentrations and terminal transferase activity as indicators of prognosis in acute non-lymphocytic leukaemia.

Authors:  L Skoog; B Nordenskjöld; A Ost; B Andersson; R Hast; N Giannoulis; S Humla; T Hägerström; P Reizenstein
Journal:  Br Med J (Clin Res Ed)       Date:  1981-06-06

10.  Biochemical characterization of adenosine deaminase (CD26; EC 3.5.4.4) activity in human lymphocyte-rich peripheral blood mononuclear cells.

Authors:  L R Costa; A K Y de Souza; J N Scholl; F Figueiró; A M O Battastini; J A Dos Santos Jaques; F F Zanoelo
Journal:  Braz J Med Biol Res       Date:  2021-05-24       Impact factor: 2.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.